Last fall at the Vision of Children Foundation Symposium in San Diego I met Dr. Michael Struck from University of Wisconsin, Madison. Dr. Struck is leading a clinical trial for the treatment of several types of Oculocutaneous Albinism.
This trial is looking at the potential benefit of treating patients with dopamine over a four month period. Researchers have found that people with Albinism are deficient in dopamine specifically in their retina. Dr. Struck is proposing that treating them with an oral dose of Levodopa could help with visual acuity and retinal function. Here is a video of Dr. Struck talking about the trial.
In order to be included in this trial, children must be over the age of three and over twenty five pounds. He is including patients of the following types of Albinism — OCA1a, OCA1b, OCA2 and unclassified OCA. The trial is taking place at the University of Wisconsin, Madison and at this time there isn’t funding for travel expenses.
If you are interested in finding out more about this trial, please click on the link and contact Dr. Struck and his team.
I am looking forward to Dr. Struck’s findings.